Recombinant human erythropoietin will lead EPO biomarkers sales through 2036 with 22.9% share of the biomarker type segment in 2026, driven by established renal care protocols and expanding therapeutic applications. The market was valued at USD 74.2 billion in 2025 and is expected to be worth USD 130.95 billion by 2036.